Entheon Biomedical Corp.
ENTBF
$0.081
-$0.0035-4.14%
OTC PK
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -60.22% | 16.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -60.22% | 16.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -100.00% | -58.60% | 29.30% |
| SG&A Expenses | -41.29% | -61.84% | -75.71% | -80.21% | -79.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.29% | -62.00% | -76.79% | -84.25% | -85.94% |
| Operating Income | -5.76% | 32.17% | 67.18% | 87.76% | 91.80% |
| Income Before Tax | -4.81% | 35.28% | -201.96% | 56.35% | 86.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.81% | 35.28% | -201.96% | 56.35% | 86.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.81% | 94.98% | 93.86% | 95.89% | 96.55% |
| EBIT | -5.76% | 32.17% | 67.18% | 87.76% | 91.80% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 17.29% | 95.63% | 94.20% | 95.90% | 96.55% |
| Normalized Basic EPS | 22.40% | -14.06% | 59.43% | 83.76% | 90.21% |
| EPS Diluted | 28.51% | 95.66% | 93.79% | 95.21% | 96.01% |
| Normalized Diluted EPS | 22.40% | -14.06% | 59.43% | 83.76% | 90.21% |
| Average Basic Shares Outstanding | 30.90% | 18.45% | 5.97% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 30.90% | 18.45% | 5.97% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |